Your browser doesn't support javascript.
loading
Dysregulated mature IL-1ß production in familial Mediterranean fever.
Migita, Kiyoshi; Izumi, Yasumori; Fujikawa, Keita; Agematsu, Kazunaga; Masumoto, Junya; Jiuchi, Yuka; Kozuru, Hideko; Nonaka, Fumiaki; Shimizu, Toshimasa; Nakamura, Tadashi; Iwanaga, Nozomi; Furukawa, Hiroshi; Yasunami, Michio; Kawakami, Atsushi; Eguchi, Katsumi.
Afiliação
  • Migita K; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Izumi Y; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Fujikawa K; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Agematsu K; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Masumoto J; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Jiuchi Y; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Kozuru H; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Nonaka F; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Shimizu T; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Nakamura T; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Iwanaga N; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Furukawa H; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Yasunami M; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Kawakami A; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
  • Eguchi K; Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehi
Rheumatology (Oxford) ; 54(4): 660-5, 2015 Apr.
Article em En | MEDLINE | ID: mdl-25240611
ABSTRACT

OBJECTIVE:

The aim of this study was to analyse the role of circulating cleaved IL-1ß in patients with FMF.

METHODS:

We enrolled 20 patients with FMF (5 males and 15 females), 22 patients with RA (4 males and 18 females) and 22 healthy controls (6 males and 16 females). Serum levels of serum amyloid A (SAA) were measured by ELISA. We also determined whether IL-1ß was present as the cleaved form (p17) in the sera of FMF patients by immunoblotting using anti-cleaved IL-1ß antibody.

RESULTS:

Although SAA concentrations were elevated in the sera, there was no significant difference in these concentrations between FMF patients and RA patients. Immunoblot analysis demonstrated that the cleaved form of IL-1ß (p17) was present in sera from FMF patients during febrile attack periods, but not in healthy controls. Bands representing the cleaved form of IL-1ß were not detected in serum from FMF patients at non-febrile attack periods or remission periods under colchicine treatment. The amounts of cleaved IL-1ß (p17) were significantly higher in patients with FMF compared with those in patients with RA in the inflammatory phase.

CONCLUSION:

The cleaved form of IL-1ß is a valuable biomarker for monitoring disease activity and response to colchicine treatment in patients with FMF. It might be useful to discriminate FMF from other non-IL-1ß-mediated inflammatory disorders.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Febre Familiar do Mediterrâneo / Proteína Amiloide A Sérica / Interleucina-1beta Tipo de estudo: Observational_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Febre Familiar do Mediterrâneo / Proteína Amiloide A Sérica / Interleucina-1beta Tipo de estudo: Observational_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article